A new class of experimental drugs called PARP inhibitors were recently presented at the San Antonio Breast Cancer Symposium (SABCS) that appear to offer promising therapeutic value for patients suffering with breast cancer. The challenge in developing the novel drugs is in better understanding which patients can be helped through their administration.
The director of the breast cancer program at the Cancer Therapy & Research Center, Virginia Kaklamani, M.D. from the UT Health Science Center in San Antonio, is currently leading an assessment that will be focused on the PARP inhibitors ( drugs that block the poly ADP ribose polymerase and that have important functions against cancer) and will try to understand which types of breast cancer PARP inhibitors can actually treat.
“These drugs are a lot more useful for a lot more patients. We just have to figure out which ones,” Dr. Virginia Kaklamani said in a press release.
The study was presented in a poster at the San Antonio Breast Cancer Symposium, a meeting that brought together the latest insights and information regarding breast cancer from all over the world. The 37th annual SABCS featured more than 7,000 researchers, oncologists and advocates who came together to discuss and share new information about the fight against breast cancer. This year, the event was presented by the Cancer Therapy & Research Center at the UT Health Science Center, and the American Association for Cancer Research and Baylor College of Medicine.
Dr. Virginia Kaklamani is collaborating with other top research centers such at Emory University, Northwestern University and the University of Wisconsin to continue her research and development of PARP inhibitors. The next step will be to analyze biopsy samples that are regularly taken during the normal course of a patient’s diagnosis and treatment to determine the best use of PARPs in a therapeutic setting.